Codiak Biosciences

Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference. Details are as follows:

Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

– Executive leader with deep regulatory experience bringing innovative biopharmaceutical products from early development to market approval – – Executive leader with deep regulatory experience bringing innovative biopharmaceutical products from early development to market approval –

Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

– Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12™ and exoSTING™, expected this year –

Codiak BioSciences Reports First Quarter 2021 Financial Results and Operational Progress

– engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic areas – – engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic areas –

Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

The stock price of Codiak BioSciences Inc (NASDAQ: CDAK) increased by over 30% during intraday trading. This is why it happened.

CDAK Stock: Over 30% Increase Intraday Explanation

– exoSTING has demonstrated enhanced potency, preferential activation of antigen presenting cells, and systemic anti-tumor immunity in vivo –

Data from Codiak's exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications Biology

– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021 –

Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways

– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients –

Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

– Healthy volunteer clinical data for exoIL-12 accepted as a late-breaking abstract –

Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association for Cancer Research (AACR) Annual Meeting

Axcella Health Inc

Denali Therapeutics

Evelo Biosciences Inc

Foghorn Therapeutics

Kaleido Biosciences Inc

Seres Therapeutics

Moderna

Rubius Therapeutics Inc

Sana Biotechnology

Sigilon Therapeutics

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,162,500 shares of its common stock at a public offering price of $21.00 per share, which includes the exercise in full of the underwriters' option to purchase 412,500 additional shares. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are anticipated to be approximately $66.4 million. The offering of the shares is expected to result in approximately $62.0 million in net proceeds to Codiak after deducting underwriting discounts and commissions and other estimated offering expenses payable by Codiak.

Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters' Option

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share, for gross proceeds of approximately $57.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Codiak. In addition, Codiak has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of its common stock, at the public offering price, less underwriting discounts and commissions. All the shares to be sold in the proposed offering will be sold by Codiak.

Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. Codiak intends to grant the underwriters a 30-day option to purchase an additional 375,000 shares of its common stock, at the public offering price, less the underwriting discounts and commissions. All the shares to be sold in the proposed offering will be sold by Codiak. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size and terms of the offering.

Codiak Announces Proposed Public Offering of Common Stock

– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity

Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients

– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –

Codiak's Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

– exoIL-12 resulted in no local or systemic treatment-related adverse events –

Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference. Details are as follows:

Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

– Human clinical testing now underway with Codiak's first two candidates, exoIL-12™ and exoSTING™ –

Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress

– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –

Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity

Aligos Therapeutics

Array Technologies

Eastern Bankshares, Inc.

Opthea

Praxis Precision Medicines

Tarsus Pharmaceuticals

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc. (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $15.00 per share, for gross proceeds of approximately $82.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being

News for Codiak Biosciences Stock (CDAK)